Raisel Iglesias Returns to Atlanta Braves, Dubón Acquired in Trade
The Atlanta Braves have re-signed veteran reliever Raisel Iglesias to a one-year, $16 million contract, as announced by the team on November 20, 2025. https://www.mlb.com/news/raisel-iglesias-signs-with-braves In a separate transaction, the Braves also acquired infielder Mauricio Dubón from the Houston astros, sending infielder Nick Allen to Houston.
Raisel Iglesias’ Return to Atlanta
Iglesias, 35, previously pitched for the Braves from 2022-2024, recording 97 saves with a 15-12 record and a 2.35 ERA. https://www.baseball-reference.com/players/i/igliesr01.shtml His 2025 season saw a slight dip in performance with a 3.21 ERA, compared to his stellar 1.95 ERA in 2024.
Since 2017, Iglesias ranks third in WAR (Wins Above Replacement) among relievers, trailing only edwin Díaz and Josh Hader. https://www.fangraphs.com/leaders.aspx?pos=RP&range=past-7yr&stats=war He also ranks second in total saves with 247, behind kenley Jansen. https://www.mlb.com/stats/leaders/r/so/2025 A notable change in his pitching approach last season was a decreased reliance on his slider and shifter, dropping from 52% usage to 38%.
Iglesias began his MLB career with the Cincinnati Reds in June 2014 and later played for the Los Angeles Angels in 2021 before being traded to the braves in 2022.
Braves Acquire Mauricio Dubón
The Braves bolstered their infield depth by acquiring Mauricio Dubón, a 31-year-old two-time gold Glove winner, from the Houston Astros. Dubón played in 133 games for Houston in 2025, batting .241.https://www.baseball-reference.com/players/d/dubonma01.shtml He won Gold Glove awards in both 2023 and 2024 for his defensive prowess.
Dubón is under contract through the end of the 2026 season and will earn a salary of $5 million in 2026.https://www.spotrac.com/mlb/player/mauricio-dubon/ Braves General Manager Alex Anthopoulos will evaluate whether to pursue a contract extension for Dubón beyond 2026.
primary Topic: MLB Transactions/Atlanta Braves
Primary Keyword: Raisel Iglesias
Secondary Keywords: Atlanta Braves, Mauricio Dubón, MLB Trade, Baseball, Free Agency, Pitcher, Infielder, Gold Glove, WAR.
Keep reading
- Arsenal Injury Update: Arteta Explains Timber Absence vs Ipswich
- FORMULA 1 Photo: September 15, 2026
- Breakthrough Salk Study Uncovers Mechanism Behind Immunotherapy Resistance: Interferons, Mitochondrial Dysfunction, and PGE2″ Interferons, mitochondrial dysfunction and PGE2: Salk study reveals mechanism behind immunotherapy resistance. Boost its search engine visibility with relevant keywords for maximum impact. Immunotherapy resistance remains one of the biggest hurdles in cancer treatment. According to a recent study published in the journal Nature Communications, scientists at the Salk Institute have made a groundbreaking discovery that sheds light on the underlying mechanisms behind this resistance. The study reveals that interferons, a type of protein that plays a crucial role in the immune system, can contribute to mitochondrial dysfunction in cancer cells. This dysfunction can lead to the production of prostaglandin E2 (PGE2), a molecule that promotes tumor growth and resistance to immunotherapy. In their study, the researchers found that PGE2 production was a key factor in the development of immunotherapy resistance in cancer cells. The team used a combination of experimental and computational models to investigate the relationship between interferons, mitochondrial dysfunction, and PGE2 production. The findings of the study suggest that targeting PGE2 production could be a potential strategy for overcoming immunotherapy resistance. The researchers propose that blocking PGE2 receptors or inhibiting its production could help restore the function of mitochondria in cancer cells, making them more susceptible to immunotherapy. The study’s authors hope that their findings will pave the way for the development of new therapies that can overcome immunotherapy resistance and improve treatment outcomes for cancer patients. Key Takeaways: – Interferons contribute to mitochondrial dysfunction in cancer cells – Mitochondrial dysfunction leads to PGE2 production, promoting tumor growth and resistance to immunotherapy – Targeting PGE2 production could be a potential strategy for overcoming immunotherapy resistance – Restoring mitochondrial function in cancer cells could make them more susceptible to immunotherapy Keywords: immunotherapy resistance, interferons, mitochondrial dysfunction, PGE2, Salk Institute, cancer treatment, breakthrough study, Nature Communications. (archyworldys.com)